RetinalGenix Technologies Inc. Files Q3 2024 10-Q

TL;DR

RetinalGenix Q3 10-Q filed. Financials updated.

AI Summary

RetinalGenix Technologies Inc. filed its Q3 10-Q report for the period ending September 30, 2024. The company, located at 1450 North McDowell Boulevard, Suite 150, Petaluma, CA 94954, operates in the Surgical & Medical Instruments & Apparatus sector. Key financial data points and changes in equity accounts are detailed within the filing.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for RetinalGenix Technologies Inc. as of the end of the third quarter of 2024.

Risk Assessment

Risk Level: low — The filing is a routine quarterly report and does not contain immediate, high-impact news.

Key Numbers

• 20240930 — Reporting Period End Date (The 10-Q covers financial information up to this date.)
• 20241118 — Filing Date (The date the report was officially submitted to the SEC.)

Key Players & Entities

• RetinalGenix Technologies Inc. (company) — Filer of the 10-Q report
• 1450 North McDowell Boulevard, Suite 150, Petaluma, CA 94954 (location) — Business and mailing address
• 3841 (industry_code) — Standard Industrial Classification for Surgical & Medical Instruments & Apparatus

FAQ

Filing Documents

• form10-q.htm (10-Q) — 641KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-24-046477.txt ( ) — 3649KB
• rtgn-20240930.xsd (EX-101.SCH) — 28KB
• rtgn-20240930_cal.xml (EX-101.CAL) — 34KB
• rtgn-20240930_def.xml (EX-101.DEF) — 130KB
• rtgn-20240930_lab.xml (EX-101.LAB) — 256KB
• rtgn-20240930_pre.xml (EX-101.PRE) — 208KB
• form10-q_htm.xml (XML) — 444KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 333-258528 RETINALGENIX TECHNOLOGIES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-3936890 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1450 North McDowell Boulevard , Suite 150 Petaluma , CA 94954 (Address of principal executive offices) (Zip Code) (415) 578-9583 (Registrant's telephone number, including area code) Not applicable (Former name, former address and former fiscal year, if changed since last report Securities registered pursuant to Section 12(b) of the Act: None Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No The number of shares of the issuer's common stock, $ 0.0001 par value per share, outstanding at November 12, 2024 was 18,090,739 . PART I — FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS. RETINALGENIX TECHNOLOGIES INC. CONSOLIDATED BALANCE SHEETS September 30, 2024 (unaudited) December 31, 2023 ASSETS Current Assets Cash $ 79,089 $ - Total Current Assets 79,089 - Equipment, net of accumulated depreciation of $ 226 and $ 151 at September 30, 2024 and December 31, 2023, respectively 81 156 Operating lease right-of-use assets 7,689 - Security deposit 1,995 - TOTAL ASSETS $ 88,854 $ 156 LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities Current Liabilities Accounts payable and accrued liabilities 885,564 884,920 Due to Sanovas 509,309 2,760 Due to related parties 477,126 457,534 Shareholders' notes payable 49,000 49,000 Lease liability – short term portion 662 - Accrued interest payable 14,479 11,599 Total Current Liabilities 1,936,140 1,405,813 Lease liability – long term portion 7,028 - Total liabilities 1,943,168 1,405,813 Stockholders' Deficit: Preferred stock, $ 0.0001 par value; 40,000,000 shares authorized; Series F preferred stock - 3,000,000 shares designated, 0 issued and outstanding at September 30, 2024 and December 31, 2023 - - Common stock, $ 0.0001 par value; 80,000,000 shares authorized; 18,060,517 and 17,635,478 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 1,806 1,764 Additional paid in capital 12,706,875 9,701,774 Accumulated deficit ( 14,562,995 ) ( 11,109,195 ) Total Stockholders' Deficit ( 1,854,314 ) ( 1,405,657 ) TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 88,854 $ 156 The accompanying notes are an integral part of these consolidated financial statements. 2 RETINALGENIX TECHNOLOGIES INC. CONSOLIDATED 2024 2023 For The Three Months Ended September 30, 2024 2023 Revenues $ - $ - Operating expenses: General and administrative expenses 244,098 167,046 Research and development 102,977 89,778 Stock-based compensation 296,256 428,683 Total operating expenses 643,331 685,507 Interest expense 960 960 Net loss $ ( 644,291 ) $ ( 686,467 ) Net loss per share - basic and diluted $ ( 0.04 ) $ ( 0.04 ) Weighted average number of common shares outstanding during the period- basic and diluted 17,970,120 17,275,635 The accompanying notes are

View Full Filing

View this 10-Q filing on SEC EDGAR